Hamilton Lane Advisors’s Aratana Therapeutics, Inc. PETX Stock Holding History

Hamilton Lane Advisors’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-111,705	Closed	-$796K	–	74
2016 Q2	$796K	Hold	111,705	–	–	0.39%	40
2016 Q1	$617K	Hold	111,705	–	–	0.29%	42
2015 Q4	$623K	Sell	111,705 -10,000	-8%	-$66.1K	0.27%	38
2015 Q3	$1.03M	Buy	+121,705	New	+$2.06M	0.51%	33

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Hamilton Lane Advisors's PETX Position: Q3 2016 in Review

Hamilton Lane Advisors sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2016, closing a stake of 111,705 shares — an estimated $796K sold.

Hamilton Lane Advisors first reported a position in PETX in Q3 2015 and held it in 4 quarters. The position peaked at $1.03M in Q3 2015. 128 funds tracked by Wall St. Rank hold PETX as of Q3 2016.

Hamilton Lane Advisors reported no remaining Aratana Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
Hamilton Lane Advisors sold 111,705 Aratana Therapeutics, Inc. shares in Q3 2016, an estimated $796K.
Hamilton Lane Advisors first reported a position in Aratana Therapeutics, Inc. in Q3 2015 and held it in 4 quarters.
Hamilton Lane Advisors's Aratana Therapeutics, Inc. position peaked at $1.03M in Q3 2015.
128 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2016.

Based on Hamilton Lane Advisors's 13F filing for Q3 2016, filed 19 Oct 2016.